AgingResearch.NewsJoin free

Beijing Continent Pharmaceutical

CompanyChina

Beijing Continent Pharmaceutical develops 2 assets, the furthest in phase 3 (AP01 in idiopathic pulmonary fibrosis). Mostly small molecule; based in China.

2
Assets
Furthest stage
Phase 3
8
Trials
2
Signals

Pipeline

2

  • AP01

    Antifibrotic agent downregulating TGF-beta and inflammatory cytokines to reduce fibroblast proliferation

    Phase 3, Small molecule, idiopathic pulmonary fibrosis, dermatomyositis interstitial lung disease

  • Hydroxynidone

    Pyridinone-based antifibrotic and anti-inflammatory small molecule

    Phase 1, Small molecule, chronic renal insufficiency

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials11
  • Signals13
  • Similar companies6

Intelligence